

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marchand et al.

Serial No.: 10/049,284

Group Art Unit: unassigned

Filed: February 11, 2002

Examiner: unassigned

For: METHODS FOR PREPARING PERFLUORINATED [ 18 F ]-RADIOLABELLED NITROIMIDAZOLE DERIVATIVES FOR CELLULAR HYPOXIA DETECTION

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

## **CITED MATERIALS**

reference(s).

Appli	ant(s) hereby disclose the information listed in the attached form PTO-1449.	
	Copies of materials listed but not attached were cited in parent application Seria No; see 37 C.F.R. § 1.98(d).	
⊠	Copies of materials listed but not attached were cited in an International Search Report dated September 22, 2000; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S PTO in the Notice of Acceptance mailed July 11, 2002.	
<u>ADDI</u>	IONAL INFORMATION	
LANGUAGE		
	All listed materials are in the English language; see 37 C.F.R. § 1.98.	
	Non-English language references:	
	The reference(s): in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): , respectively.	
	☐ (An) English-language translation(s) of the references: is (are) provided.	
	☐ A commercial English-language abstract of reference(s) is (are) provided.	
	An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a	

counterpart foreign application, is provided indicating the relevance of the cited

**FEES** 

$\boxtimes$	No fee is required for this Information Disclosure Statement because:
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
	☐ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
	☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
	A fee is required for this Information Disclosure Statement:
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
	This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.
CERT	FICATION
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

## **DEPOSIT ACCOUNT**

If a fee is due, attached is a check in the amount of \$\frac{\\$}{.}\$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Harry B. Shubin, Reg. No. 32,004 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: DCLERC-1

Date: August 28 2002

HBS:ghp